In contrast to our results, Dobay et al. observed higher TET2 mutation rates in TFH-derived PTCL (64%) and F-PTCL (75%) than in AITL (48%) [5]. The gene discussed is TET2; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.